Trial Profile
Safety, Tolerability and Pharmacokinetics of Single Rising Intravenous Dose and Single Subcutaneous Dose of BI 655130 in Healthy Japanese Male Volunteers (Double-blind, Randomised, Placebo-controlled Design).
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 13 Mar 2024
Price :
$35
*
At a glance
- Drugs Spesolimab (Primary) ; Spesolimab (Primary)
- Indications Palmoplantar pustulosis; Pustular psoriasis; Ulcerative colitis
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 01 Dec 2022 Results from Phase I Clinical Studies ( NCT02525679, NCT02852824, NCT03100903, NCT03123094, NCT03617835 ) assessing pharmacokinetics of spesolimab and evaluate changes with respect to dose, frequency of dosing, formulation and injection site. Immunogenicity, safety and tolerability published in the Clinical Pharmacokinetics
- 09 Jan 2018 Status changed from active, no longer recruiting to completed.
- 06 Nov 2017 Planned End Date changed from 16 Dec 2017 to 5 Jan 2018.